Is there a specific reason why the big anti-viral players (GILD, GSK, etc.) haven't developed any RSV treatment (beyond the vaccines)? You would think that this would be a lucrative enough opportunity and they would have at least tried over the years. Perhaps they have, I just don't know the full back-story on attempted anti-RSV drugs over the years. Or perhaps not as lucrative an opportunity to the bigger players because a good portion get the vaccine and not as much of a need for an active treatment against RSV?
Compared to ENTA’s previous slide set (from the Leerink webcast—see #msg-128740228), slide #16 in the current slide set, which pertains to the design of FXR agonists, is new.
(Three slides from the old slide set pertaining to rat data have been removed, so there are two fewer slides, all told, in the current slide set.)
Market Data 
Markets 
AI
